These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32505969)

  • 21. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics.
    Janto K; Prichard JR; Pusalavidyasagar S
    J Clin Sleep Med; 2018 Aug; 14(8):1399-1408. PubMed ID: 30092886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
    Winrow CJ; Renger JJ
    Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.
    Mahoney CE; Mochizuki T; Scammell TE
    Sleep; 2020 Jun; 43(6):. PubMed ID: 31830270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
    Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
    Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities.
    Carpi M; Palagini L; Fernandes M; Calvello C; Geoffroy PA; Miniati M; Pini S; Gemignani A; Mercuri NB; Liguori C
    Neuropharmacology; 2024 Mar; 245():109815. PubMed ID: 38114045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis.
    Na HJ; Jeon N; Staatz CE; Han N; Baek IH
    Sleep; 2024 Feb; 47(2):. PubMed ID: 37950346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
    Bonaventure P; Shelton J; Yun S; Nepomuceno D; Sutton S; Aluisio L; Fraser I; Lord B; Shoblock J; Welty N; Chaplan SR; Aguilar Z; Halter R; Ndifor A; Koudriakova T; Rizzolio M; Letavic M; Carruthers NI; Lovenberg T; Dugovic C
    J Pharmacol Exp Ther; 2015 Sep; 354(3):471-82. PubMed ID: 26177655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.
    Sanchez-Alavez M; Benedict J; Wills DN; Ehlers CL
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30715515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review.
    Kishi T; Koebis M; Sugawara M; Kawatsu Y; Taninaga T; Iwata N
    Transl Psychiatry; 2024 Sep; 14(1):374. PubMed ID: 39277609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine.
    Yao L; Ramirez AD; Roecker AJ; Fox SV; Uslaner JM; Smith SM; Hodgson R; Coleman PJ; Renger JJ; Winrow CJ; Gotter AL
    J Neurochem; 2017 Jul; 142(2):204-214. PubMed ID: 28444767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.
    Roecker AJ; Mercer SP; Bergman JM; Gilbert KF; Kuduk SD; Harrell CM; Garson SL; Fox SV; Gotter AL; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4992-4999. PubMed ID: 25613676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suvorexant: first global approval.
    Yang LP
    Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new class of sedative/hypnotics: dual orexin receptor antagonists.
    Simonson W
    Geriatr Nurs; 2014; 35(6):462-3. PubMed ID: 25457290
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
    Struyk A; Gargano C; Drexel M; Stoch SA; Svetnik V; Ma J; Mayleben D
    Eur Neuropsychopharmacol; 2016 Oct; 26(10):1649-56. PubMed ID: 27554636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
    Raheem IT; Breslin MJ; Bruno J; Cabalu TD; Cooke A; Cox CD; Cui D; Garson S; Gotter AL; Fox SV; Harrell CM; Kuduk SD; Lemaire W; Prueksaritanont T; Renger JJ; Stump C; Tannenbaum PL; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Feb; 25(3):444-50. PubMed ID: 25577040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct effects of orexin receptor antagonist and GABA
    Seol J; Fujii Y; Park I; Suzuki Y; Kawana F; Yajima K; Fukusumi S; Okura T; Satoh M; Tokuyama K; Kokubo T; Yanagisawa M
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24353-24358. PubMed ID: 31712421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
    Roecker AJ; Reger TS; Mattern MC; Mercer SP; Bergman JM; Schreier JD; Cube RV; Cox CD; Li D; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4884-90. PubMed ID: 25248679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PSPH-D-18-00526: Effect of a dual orexin receptor antagonist (DORA-12) on sleep and event-related oscillations in rats exposed to ethanol vapor during adolescence.
    Ehlers CL; Benedict J; Wills D; Sanchez-Alavez M
    Psychopharmacology (Berl); 2020 Oct; 237(10):2917-2927. PubMed ID: 31659377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.